Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Tissue bank sits at the center of this dementia and brain health question.
Tissue banks play a vital role in advancing Alzheimer’s research by collecting, preserving, and distributing donated brain tissue to scientists worldwide. When families donate a loved one’s brain through established research programs, they enable researchers to study the pathological changes that occur in Alzheimer’s disease—including amyloid plaques, tau tangles, and neurodegeneration—at the microscopic level. A single donated brain can provide tissue samples for hundreds of individual research studies, making tissue donations one of the most impactful contributions to accelerated scientific progress. The National Institute on Aging supports 27 Alzheimer’s Disease Centers (ADCs) across the United States, each equipped with neuropathology cores that process and distribute these precious resources to qualified researchers.
This year alone, the National Institutes of Health allocated $3.98 billion in overall resources for Alzheimer’s and related dementias research, with an additional $113 million in new research funding designated for FY 2026. Much of this funding depends on the availability of human brain tissue. Without the generosity of families who donate brain tissue, researchers would lack the essential biological materials needed to understand disease mechanisms, validate biomarkers, and test new therapeutic approaches. Brain donation through organized research programs comes at no financial cost to families and does not delay funeral arrangements, removing major barriers that previously prevented people from participating in this critical work.
Table of Contents
- How Tissue Banks Preserve Brain Tissue for Future Research
- The Critical Role of Neuropathology in Alzheimer’s Understanding
- Scale and Impact of Current Tissue Banking Networks
- The Logistics and Practicalities of Brain Donation
- Challenges and Limitations in Current Tissue Banking Systems
- The Connection Between Tissue Banking and Clinical Trial Development
- The Future of Brain Tissue Research and Emerging Opportunities
- Conclusion
- Frequently Asked Questions
How Tissue Banks Preserve Brain Tissue for Future Research
Tissue banks maintain highly specialized infrastructure designed to preserve brain tissue in ways that keep the biological material viable for decades of research. The Michigan Brain Bank, operating in partnership with the Michigan Alzheimer’s Disease Research Center, exemplifies this commitment by maintaining approximately 1,500 paraffin-embedded brains and 1,100 frozen brains. These different preservation methods serve different research purposes: paraffin-embedded tissue is ideal for microscopy and immunohistochemistry studies examining cellular pathology, while frozen tissue preserves biochemical integrity for molecular biology experiments, protein analysis, and genetic studies. The NIH-supported NeuroBioBank Network coordinates six regional brain banks to provide centralized collection and distribution of human postmortem brain tissue. This coordinated approach ensures that tissue quality meets strict standards, that researchers can access samples for their work, and that valuable tissue is not wasted due to poor preservation or duplication of efforts.
Each participating brain bank follows standardized protocols for collection, processing, and storage, allowing data and samples to be compared across different research groups. The standardization also accelerates research by removing barriers that would otherwise exist between institutions seeking to study similar disease processes. One important limitation to understand: not all donated tissue becomes immediately available for research. Quality control processes take time, comprehensive neuropathological examination by trained specialists must be completed, and tissue samples must be carefully catalogued and integrated into the bank’s distribution system. Families should expect a processing period of several months to a year before tissue enters active research use, though this timeline ensures that only high-quality material reaches scientists.
The Critical Role of Neuropathology in Alzheimer’s Understanding
Neuropathology—the microscopic examination of brain tissue—remains the gold standard for confirming Alzheimer’s disease diagnosis. During life, physicians can identify cognitive decline and sometimes detect biomarkers through blood tests or brain imaging, but only through postmortem neuropathological examination can researchers definitively see the pathological hallmarks of Alzheimer’s: amyloid-beta plaques, phosphorylated tau tangles, and neuroinflammatory changes. Each tissue sample provides researchers with an opportunity to examine how these pathologies relate to cognitive symptoms, how they progress across different brain regions, and how they interact with other age-related changes like Lewy bodies (associated with Parkinson’s disease) or TDP-43 inclusions (associated with frontotemporal dementia). This neuropathological examination serves purposes far beyond academic interest. Researchers use tissue banks to validate whether blood biomarkers accurately reflect brain pathology, work that is essential for developing and refining diagnostic tests. They study tissue from people who remained cognitively normal despite having significant amyloid and tau pathology—a group called “resistant” individuals—to understand what protective factors might prevent cognitive decline.
They examine tissue from individuals with rare or atypical presentations of dementia to expand understanding of disease heterogeneity. Without access to human brain tissue through these systematic collections, researchers would be limited to studying disease in animal models, which, while valuable, cannot fully replicate the complexity of human neurodegeneration. A critical caveat: tissue banks cannot solve all research questions on their own. Tissue provides a snapshot of the brain at one moment in time (death), and it cannot answer questions about how disease progresses over years or decades. It also cannot assess the effects of living patients’ medications, lifestyle choices, or medical conditions during life in ways that living research participants can. Modern Alzheimer’s research increasingly combines tissue-based studies with longitudinal studies of living participants who undergo repeat cognitive testing, brain imaging, and biomarker assessment.
Scale and Impact of Current Tissue Banking Networks
The accessibility of brain tissue through organized networks has transformed the research landscape. When researchers propose a study examining, for example, how inflammation markers differ in Alzheimer’s tissue versus healthy aging, they can now submit a request to a tissue bank, receive carefully matched samples from multiple donors, and begin experiments within weeks. This efficiency would have been impossible thirty years ago when researchers typically had access only to tissue collected locally at their own institutions. The NeuroBioBank Network’s coordination of six brain banks ensures that a researcher in Boston can access tissue from a diverse population including donors from the Midwest, South, and West Coast, improving the generalizability of findings.
The Michigan Brain Bank’s collection of over 2,600 preserved brains represents decades of accumulated contributions from families across Michigan and beyond. This collection supports dozens of active research projects annually, ranging from studies of early-stage Alzheimer’s pathology to investigations of how Alzheimer’s disease intersects with other neurodegenerative conditions. The researchers using these samples publish peer-reviewed papers that advance the field’s understanding of disease mechanisms and support the development of new therapeutic strategies. Without the initial donation decisions made by these families—often during emotionally difficult periods following a loved one’s death—the current rate of scientific progress would be substantially slower.
The Logistics and Practicalities of Brain Donation
For families considering brain donation, understanding the practical process removes a major source of anxiety. When someone with cognitive decline or dementia passes away, the family contacts a research program or tissue bank they may have previously enrolled in, or they reach out to the Alzheimer’s Association for information on how to proceed. A trained technician performs a quick postmortem assessment and arranges rapid transport of the brain to the tissue bank’s processing facility, typically within hours of death. Throughout this process, funeral arrangements proceed normally—families can have viewings, funerals, and memorials as planned, and the donated brain does not delay any of these services. The tissue bank’s staff then performs a detailed neuropathological examination, documenting the microscopic changes present in the brain.
High-quality photographs and detailed descriptions are recorded, tissue samples are collected and preserved using multiple methods, and all information is carefully catalogued. Families later receive a report describing the neuropathological findings, providing them with information about what pathological changes were present in their loved one’s brain. This report can be valuable for other family members who may be concerned about their own risk of developing cognitive decline, as it provides concrete information about disease pathology rather than speculation. A practical consideration families often face: should brain donation be discussed before someone develops significant cognitive impairment, or can arrangements be made after diagnosis? Research programs find that advance discussions with families about brain donation wishes—similar to discussing organ donation or end-of-life preferences—lead to better outcomes and higher donation rates. Families who have time to think about the decision and discuss it with their loved one experience less conflict and greater peace of mind that they are honoring their relative’s values.
Challenges and Limitations in Current Tissue Banking Systems
One significant challenge facing tissue banks is demographic underrepresentation. The majority of brain tissue in current collections comes from populations of European ancestry, while tissue from African American, Hispanic, Asian American, and other populations is substantially underrepresented. This creates a research gap: Alzheimer’s disease affects different populations at different rates, and emerging research suggests that genetic and environmental factors may influence disease pathology and expression differently across ancestries. Understanding these differences requires studying brain tissue from diverse populations, yet the legacy of medical discrimination and lower rates of research participation among some communities have resulted in tissue banks that do not adequately represent the diversity of people who develop dementia. Tissue banks also face funding constraints that limit their capacity to expand and modernize.
High-quality preservation, careful neuropathological examination, and detailed record-keeping require significant resources. Storage facilities must maintain precise temperatures, equipment requires regular calibration and maintenance, and trained staff must complete their work regardless of whether research funding is abundant or scarce. These operational costs do not typically attract grant funding that researchers can use to advance their scientific aims, creating a hidden challenge for tissue banks seeking to maintain and grow their collections. A limitation that may not be immediately apparent: not all pathological findings require tissue examination. Increasingly, researchers can study biomarkers (like phosphorylated tau or amyloid-beta) in blood samples or cerebrospinal fluid from living individuals, reducing some of the traditional need for tissue-based research. This is actually positive for accelerating some types of research, but it means tissue banks must continuously evolve their purpose, emphasizing questions that can only be answered through detailed microscopic examination of actual brain structure and cellular interactions.
The Connection Between Tissue Banking and Clinical Trial Development
The insights gained from tissue banking research directly inform the development of new treatments tested in clinical trials. When researchers discover that a particular therapeutic target—such as reducing amyloid-beta or stabilizing tau protein—shows promise in tissue-based studies, that information guides decisions about which molecular targets are worth pursuing through drug development pipelines. Companies and research institutions invest millions of dollars developing and testing potential new treatments, but tissue banks provide the foundational evidence suggesting which approaches are biologically plausible and most likely to succeed.
For example, much of the enthusiasm surrounding monoclonal antibody treatments targeting amyloid-beta stems partly from tissue bank studies demonstrating the relationship between amyloid pathology and neurodegeneration. Researchers were able to examine tissue from people who had received experimental anti-amyloid treatments to see whether the treatments successfully reduced amyloid burden and whether this reduction correlated with preservation of neurons and synapses. This tissue-based evidence supported the continued development of treatments like aducanumab and lecanemab, which have now advanced through clinical trials and received FDA approval.
The Future of Brain Tissue Research and Emerging Opportunities
Looking forward, tissue banks are expanding their focus beyond traditional neuropathology toward new research applications. Advanced techniques like single-cell RNA sequencing can now reveal which genes are expressed in specific cell types within brain tissue, providing unprecedented insight into the molecular basis of neurodegeneration. Researchers can examine not just neurons but also the glial cells (astrocytes, microglia, oligodendrocytes) that support neural function and contribute to neuroinflammation.
These capabilities require access to high-quality tissue samples, making tissue banks even more essential to modern neuroscience. Tissue banking networks are also placing increasing emphasis on enrolling diverse participants and ensuring that future research benefits all communities affected by dementia. Outreach programs in partnership with community organizations, culturally tailored education about brain donation, and intentional recruitment from underrepresented populations are gradually shifting the composition of tissue collections toward greater demographic diversity. This shift will eventually enable researchers to address questions about how Alzheimer’s disease pathology and progression might vary across different genetic backgrounds and environmental exposures.
Conclusion
Tissue bank contributions form the foundation supporting future advances in Alzheimer’s research. The biological material donated by families enables scientists to examine the pathological changes of dementia at the microscopic level, validate new biomarkers and diagnostic tests, and understand the molecular mechanisms driving cognitive decline. With $3.98 billion in annual NIH funding for Alzheimer’s and related dementias research, and an additional $113 million in new funding designated for 2026, researchers have the financial resources to conduct sophisticated studies—but only if they have access to the human brain tissue that such studies require.
The 27 NIH-supported Alzheimer’s Disease Centers, the NeuroBioBank Network’s coordinated system of six brain banks, and collections like the Michigan Brain Bank collectively serve thousands of researchers globally, demonstrating the reach and impact of tissue donation. For families considering whether to participate in brain donation, the decision offers a meaningful way to contribute to scientific progress while creating no burden on funeral arrangements or adding costs to families. Organizations like the Alzheimer’s Association provide information on how to register for brain donation programs and can connect families with tissue banks in their region. By ensuring that tissue banks have access to diverse and representative samples from communities across the United States, families not only support research that may help future generations but also help ensure that the benefits of scientific progress reach all people affected by dementia.
Frequently Asked Questions
How long does the brain donation process take from start to finish?
The actual tissue collection typically occurs within a few hours of death. However, the full neuropathological examination and tissue processing can take several months to over a year before samples are fully catalogued and available for distribution to researchers. Families usually receive a neuropathology report with findings about a year after donation.
Will brain donation delay my loved one’s funeral?
No. Brain donation through established research programs does not delay or interfere with funeral arrangements, viewings, cremation, or burial. The family can proceed with all planned services on their original schedule.
Is there any cost to families who donate brain tissue?
No. Brain donation through research programs is completely free for families. All costs associated with collection, preservation, and examination are covered by research funding and tissue bank budgets.
Can people with mild cognitive impairment or normal cognition donate their brains?
Yes. Tissue banks accept donations from people across the cognitive spectrum—those with normal cognition, mild cognitive impairment, dementia, and those with cognitive decline attributed to other causes. This diversity of samples helps researchers understand how pathology differs across stages of disease severity.
How many researchers can use tissue from a single donated brain?
A single donated brain can provide tissue samples for hundreds of individual research studies conducted by different research groups over many years. The tissue is carefully parceled into smaller samples, each preserved for a specific research purpose, maximizing the scientific benefit of each donation.
What if my family has a history of Alzheimer’s or dementia? Is my brain tissue especially valuable for research?
Yes, tissue from people with a family history of Alzheimer’s is particularly valuable because researchers can study inherited patterns of pathology and compare findings with genetic data. However, tissue from people without family history is also essential—researchers study it to understand sporadic Alzheimer’s disease and to identify protective factors in people without genetic risk.
You Might Also Like
- Anthropological Research Examines Cultural Approaches to Alzheimer’s Care
- Rapid Diagnostic Test Development Targets Alzheimer’s Primary Care Settings
- Interprofessional Education Programs Prepare Teams for Alzheimer’s Care
For more, see Alzheimer’s Association — clinical trials.
